{"url_path":"/sec/labt/8-k/2026-07-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/2079272/0001213900-26-078328-index.html","accession_number":"0001213900-26-078328","cik":"0002079272","ticker":"LABT","issuer_name":"Lakewood-Amedex Biotherapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2079272/0001213900-26-078328-index.html","primary_entity_key":"0002079272","primary_entity_name":"Lakewood-Amedex Biotherapeutics Inc."},"word_count":213,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n** **\n\nOn July 15, 2026, Lakewood-Amedex Biotherapeutics\nInc. (the “Company”) made available a corporate investor presentation (the “Investor Deck”) that the Company intends\nto use from time to time in meetings and discussions with investors, analysts, and other third parties. The Investor Deck includes, among\nother things, the Company's development of Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials designed\nto address drug-resistant infections and the global threat of antimicrobial resistance. It further describes the Company's lead program,\nNu-3, a topically delivered antimicrobial gel selected for clinical development for the treatment of infected diabetic foot ulcers (iDFU),\ntogether with related preclinical and clinical data, regulatory strategy, intellectual property portfolio, competitive landscape, and\nmanagement team information.\n\n** **\n\nA copy of the Investor Deck is attached hereto\nas Exhibit 99.1 and is incorporated by reference herein.\n\n \n\nThe information contained in this Current Report\non Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section\n18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under\nthe Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}